[go: up one dir, main page]

BR0108974A - 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios - Google Patents

3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios

Info

Publication number
BR0108974A
BR0108974A BR0108974-9A BR0108974A BR0108974A BR 0108974 A BR0108974 A BR 0108974A BR 0108974 A BR0108974 A BR 0108974A BR 0108974 A BR0108974 A BR 0108974A
Authority
BR
Brazil
Prior art keywords
substituted
alkyl
aryl
oxdiazol
cycloalkyl
Prior art date
Application number
BR0108974-9A
Other languages
English (en)
Inventor
Karl Schoenafinger
Stefan Petry
Guenter Mueller
Karl-Heinz Baringhaus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0108974A publication Critical patent/BR0108974A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"3-FENIL-5-ALCóXI-1,3,4-OXDIAZOL-2-ONAS SUBSTITUìDAS E SEU USO PARA A INIBIçãO DAS LIPASES SENSìVEIS A HORMÈNIOS". São descritas 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituídas da fórmula (1), em que R^ 1^ significa C~ 1~-C~ 6~-alquila e C~ 3~-C~ 9~-cicloalquila substituídas, R^ 2^, R^ 3^, R^ 4^ e R^ 5^ significam hidrogênio, halogênio, nitro, C~ 1~-C~ 4~-alquila, C~ 1~-C~ 9~-alquilóxi; C~ 6~-C~ 10~-aril-C~ 1~-C~ 4~-alquilóxi, C~ 6~-C~ 10~-arilóxi, C~ 6~-C~ 10~-arila, C~ 3~-C~ 8~cicloalquila ou O-C~ 3~-C~ 8~-cicloalquila substituídas; ou 2-oxo-pirrolidin-1-ila, 2,5-dimetilpirrol-1-ila ou NR^ 6^-A-R^ 7^, com a condição de que R^ 2^, R^ 3^, R^ 4^ e R^ 5^ não signifiquem simultaneamente hidrogênio e pelo menos um dos radicais R^ 2^, R^ 3^, R^ 4^ ou R^ 5^ represente o radical 2-oxo-pirrolidin-1-ila, 2,5-dimetilpirrol-1-ila ou NR^ 6^-A-R^ 7^, com R^ 6^ = hidrogênio, C~ 1~-C~ 4~-alquila ou C~ 6~-C~ 10~-aril-C~ 1~-C~ 4~-alquila substituída, A = uma ligação simples, CO~ n~ SO~ n~ ou CONH, n = 1 ou 2, R^ 7^ = hidrogênio, C~ 1~-C~ 18~-alquila, C~ 2~-C~ 18~-alquenila, C~ 6~-C~ 10~-aril-C~ 1~-C~ 4~-alquila, C~ 5~-C~ 8~-cicloalquil-C~ 1~-C~ 4~-alquila, C~ 5~-C~ 8~-cicloalquila, C~ 6~-C~ 10~-aril-C~ 2~-C~ 6~-alquenila, C~ 6~C~ 10~-arila, difenila, difenil-C~ 1~ -C~ 4~-alquila, indanila substituídas ou o grupo Het(CH~ 2~)~ r~-, com r = 0, 1, 2 ou 3 e Het = heterociclo saturado ou insaturado com 5-7 elementos, que pode ser benzoanelado e substituído, bem como um processo para a sua preparação. Os compostos apresentam uma efeito inibidor sobre as lipases sensíveis a hormónios, HSL.
BR0108974-9A 2000-03-07 2001-02-20 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios BR0108974A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (1)

Publication Number Publication Date
BR0108974A true BR0108974A (pt) 2003-06-03

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108974-9A BR0108974A (pt) 2000-03-07 2001-02-20 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios

Country Status (28)

Country Link
US (1) US6369088B2 (pt)
EP (1) EP1263745B1 (pt)
JP (1) JP2003525931A (pt)
KR (1) KR100790763B1 (pt)
CN (1) CN1261419C (pt)
AR (1) AR027611A1 (pt)
AT (1) ATE267184T1 (pt)
AU (1) AU784827B2 (pt)
BR (1) BR0108974A (pt)
CA (1) CA2401953A1 (pt)
DE (1) DE50102325D1 (pt)
DK (1) DK1263745T3 (pt)
EE (1) EE04877B1 (pt)
ES (1) ES2218383T3 (pt)
HK (1) HK1054036B (pt)
HR (1) HRP20020732A2 (pt)
HU (1) HUP0302772A3 (pt)
IL (1) IL151518A (pt)
MX (1) MXPA02008038A (pt)
NO (1) NO323483B1 (pt)
NZ (1) NZ521207A (pt)
PL (1) PL359702A1 (pt)
PT (1) PT1263745E (pt)
RU (1) RU2281283C2 (pt)
SK (1) SK12752002A3 (pt)
TR (1) TR200401217T4 (pt)
WO (1) WO2001066531A1 (pt)
YU (1) YU57802A (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
AR074978A1 (es) 2008-12-23 2011-03-02 Bial Portela & Ca Sa 3-n-aril-1,3,4-oxadiazolonas 5-o-sustituidas para uso en el tratamiento del dolor y procedimiento de obtencion
EP2543660A4 (en) * 2010-03-04 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
ES2836973T3 (es) 2011-12-12 2021-06-28 Receptos Llc Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
US9260427B2 (en) 2013-06-11 2016-02-16 Receptos, Inc. GLP-1 receptor modulators
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
JP2017538711A (ja) 2014-12-10 2017-12-28 セルジーン インターナショナル ツー エスエーアールエル Ｇｌｐ−１レセプターモジュレーター
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
CN113227093A (zh) 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
DE3267258D1 (en) 1981-06-15 1985-12-12 Shell Int Research 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
NZ521207A (en) 2005-04-29
HUP0302772A2 (hu) 2003-11-28
CN1416424A (zh) 2003-05-07
AU3378701A (en) 2001-09-17
EP1263745B1 (de) 2004-05-19
AU784827B2 (en) 2006-06-29
EE04877B1 (et) 2007-08-15
WO2001066531A1 (de) 2001-09-13
CN1261419C (zh) 2006-06-28
DK1263745T3 (da) 2004-08-16
NO323483B1 (no) 2007-05-21
AR027611A1 (es) 2003-04-02
MXPA02008038A (es) 2004-04-05
WO2001066531A8 (de) 2002-07-25
EP1263745A1 (de) 2002-12-11
KR20020079986A (ko) 2002-10-21
HK1054036A1 (en) 2003-11-14
YU57802A (sh) 2005-07-19
RU2281283C2 (ru) 2006-08-10
US20010031772A1 (en) 2001-10-18
DE50102325D1 (de) 2004-06-24
HK1054036B (zh) 2006-11-17
ATE267184T1 (de) 2004-06-15
TR200401217T4 (tr) 2004-06-21
ES2218383T3 (es) 2004-11-16
CA2401953A1 (en) 2001-09-13
EE200200498A (et) 2004-02-16
JP2003525931A (ja) 2003-09-02
HUP0302772A3 (en) 2007-03-28
HRP20020732A2 (en) 2004-12-31
NO20024201L (no) 2002-09-03
US6369088B2 (en) 2002-04-09
PT1263745E (pt) 2004-09-30
KR100790763B1 (ko) 2008-01-03
IL151518A (en) 2008-06-05
NO20024201D0 (no) 2002-09-03
PL359702A1 (en) 2004-09-06
IL151518A0 (en) 2003-04-10
SK12752002A3 (sk) 2003-04-01

Similar Documents

Publication Publication Date Title
BR0108974A (pt) 3-fenil-5-alcóxi-1,3,4-oxdiazol-2-onas substituìdas e seu uso para a inibição das lipases sensìveis a hormÈnios
BR9806296B1 (pt) compostos de ácido sulfìnico, mistura, composição e uso dos mesmos.
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
BR9910029A (pt) Hidróxi indóis, sua aplicação como inibidores da fosfodiesterase 4 e processo para sua preparação
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
PE107699A1 (es) Derivados de oxindol sustituidos
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
TR199902203T2 (xx) Fernesil transferaz engelleyici, N-veya C-ba�lant�l� imidazoller ile ikame edilmi� 1,8-anele kinolinon t�revleri.
AR002740A1 (es) Compuesto derivado de la isotiazolona y formulacion farmaceutica con el mismo.
BR0112456A (pt) Compostos de piperidina para uso como inibidores de ccr-3
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
BR0200982A (pt) Compostos do ácido alfa-amino sulfonila, um processo para sua preparação e composições farmacêuticas compreendendo os mesmos
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ES2189941T3 (es) Derivados de nucleosidos aciclicos.
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
DK71780A (da) Fremgangsmaade til fremstilling af difenylhydantoinderivater
BR112022018828A2 (pt) Derivados de benzodiazepina como gaba a gamma1 pams
BR9809496A (pt) Composto, processo para produzi-lo, uso do mesmo, preparação farmacêutica, e, processo para tratar pacientes necessitados de tratamento.
BR0213731A (pt) Compostos de silìcio
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A,10A E 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.